orserdu
stemline therapeutics b.v. - elacestrant - rintojen kasvaimet - endokriinihoito - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
fareston
orion corporation - toremifeenin - rintojen kasvaimet - endokriinihoito - hormoniriippuvaisen metastasoituneen rintasyövän ensimmäinen rintuhormonihoito postmenopausaalisilla potilailla. farestonia ei suositella potilaille, joilla on estrogeeni-reseptoriin negatiiviset kasvaimet.
faslodex
astrazeneca ab - fulvestrantti - rintojen kasvaimet - hormonaalisen hoidon, anti-estrogeenit - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. pre - tai huonomaineiset naiset, yhdistelmä-hoidon palbociclib olisi yhdistettävä luteinisoivan hormonin vapauttava hormoni (lhrh) - agonisteilla.
tamofen 10 mg tabletti
bayer oy - tamoxifeni citras - tabletti - 10 mg - tamoksifeeni
tadex 10 mg tabletti
orion corporation - tamoxifen citrate - tabletti - 10 mg - tamoksifeeni
tamofen 20 mg tabletti
bayer oy - tamoxifeni citras - tabletti - 20 mg - tamoksifeeni
tadex 20 mg tabletti
orion corporation - tamoxifen citrate - tabletti - 20 mg - tamoksifeeni
fareston 20 mg tabletti
orion corporation - toremifene citrate - tabletti - 20 mg - toremifeeni
fulvestrant sandoz 250 mg injektioneste, liuos, esitäytetty ruisku
sandoz a/s - fulvestrant - injektioneste, liuos, esitäytetty ruisku - 250 mg - fulvestrantti
fulvestrant ratiopharm 250 mg injektioneste, liuos, esitäytetty ruisku
teva b.v. - fulvestrant - injektioneste, liuos, esitäytetty ruisku - 250 mg - fulvestrantti